Low Doses Of Humanized Anti-Cd20 Antibody Reported Active In Non-Hodgkin's Lymphoma

... Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, presented on Sunday, December 10th, follow-up clinical data that showed the Company's humanized anti-CD20 (hA20) monoclonal antibody was active in patients with non-Hodgkin's lymphoma (NHL) at a dose as low as 120 mg/m(2). [click link for full article] ...